Sapheon Inc. has been acquired by Covidien plc
Sapheon Inc., based in Santa Rosa, California, has been acquired by the Irish Covidien plc, a global healthcare products leader dedicated to innovation and long-term growth. Financial details have not been disclosed.
Sapheon Inc. is a medical device company whose mission is to develop new approaches and disruptive technologies for the treatment of vascular disease. The company’s current focus is the VenaSeal Sapheon Closure System, a novel treatment for venous reflux disease. Sapheon, Inc. will operate as a subsidiary of Covidien plc.
Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Through its Medical Devices and Medical Supplies segments, the company creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Michael S. Goldman
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider
Holland Capital, a Netherlands-based private equity firm, has acquired a stake in Top Systems, a leading provider of complete battery-based power solutions, with a unique value-added services proposition.
Learn moreInfotreasury has been sold to Matera
Matera, a leading banking software company with world-class instant payments and core banking solutions, has acquired Infotreasury.
Learn moreThrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH
Paradiesfrucht GmbH, a gobal freeze dryer of fruits, fruit preparations, drops, powders and granulates, has been acquired by Thrive Freeze Dry (Thrive), a portfolio company of Entrepreneurial Equity Partners (e2p) and Mubadala Capital. The transaction is expected to close in 2024, subject to customary closing conditions, including antitrust approval.
Learn more